France will become the first country in the European Union to reimburse anti-obesity drugs through its public healthcare system, Health Minister Stéphanie Rist announced on Thursday (28 May).
From mid-June, severely obese patients in France will be able to receive partial or full reimbursement for weight-loss injections Wegovy and Mounjaro under the national social security system.
The move marks a major shift in access to obesity treatment in Europe, where the high cost of the drugs has remained a barrier for many patients.
“We are the first country in the European Union to provide reimbursement for patients who need it, under general law, on a permanent basis,” Rist said during an interview with TF1 television.
The treatment will be available to adults with severe obesity who meet strict medical criteria.
Patients with a body mass index (BMI) of at least 35 and at least one obesity-related illness will qualify. Those with a BMI of 40 or above will also be eligible, even without additional health conditions.
The drugs will officially be reimbursed at a rate of 65%. However, Rist said most eligible patients are likely to receive full coverage because many already qualify for 100% reimbursement due to related medical conditions.
“The target population is around one million people. However, this does not mean that everyone will receive the treatment, as it always depends on the individual case and the doctor’s prescription,” she said.
Wegovy, produced by Danish pharmaceutical company Novo Nordisk, and Eli Lilly’s Mounjaro have become some of the world’s most sought-after obesity treatments in recent years.
The drugs help patients lose weight by regulating appetite and blood sugar levels. Demand has surged globally as governments and healthcare systems seek ways to tackle rising obesity rates.
In France, the treatments have been available by prescription since 2024, but patients have until now had to cover the cost themselves. Monthly treatment costs average around €300.
Rist estimated the reimbursement programme would eventually cost the French state around €100 million per year as prescriptions increase.
Last year, France also widened access by allowing all doctors, not just specialists such as endocrinologists, to prescribe the treatments.
According to a French study published in 2024, around 18% of France’s population - roughly 10 million people - are obese.
As of January this year, more than 70,000 patients in France were already being treated with Mounjaro, according to estimates.
Health officials said the reimbursement programme is intended to help patients suffering from chronic obesity-related conditions rather than support cosmetic weight loss.
“It addresses a growing public health challenge and the urgency of appropriate therapeutic care,” said Étienne Tichit, General Manager of Novo Nordisk France.
Mike Doustdar, president and chief executive of Novo Nordisk, said the decision showed “the foresight and maturity of the French system.”
The decision comes as competition in the obesity drug market continues to intensify.
Novo Nordisk and Eli Lilly have both launched oral versions of their weight-loss treatments in the U.S. Last week, the European Medicines Agency recommended approval of Novo Nordisk’s Wegovy pill, which could become the first oral anti-obesity drug available in Europe.
In the UK, weight-loss drugs including Wegovy and Mounjaro are available on the NHS, but access remains limited under strict eligibility criteria. Patients typically need to meet BMI thresholds and have obesity-related health conditions.
Azerbaijan is seeking to attract more European visitors by improving air connectivity and raising its profile as an international tourism des...
Russia says no plague cases have been detected among contacts of a laboratory worker who died in Siberia, with most tests negative for infectious d...
Space-agency chiefs and industry leaders met to discuss lunar exploration, satellite networks and orbital security on Tuesday as a major global spa...
Australian counterterrorism authorities are examining the links of the co-pilot accused of attacking the captain and attempting to take control of a flydubai flight bound for Israel. Authorities in New Zealand have also said they are investigating reports the suspect had spent time in that country.
Right-wing Brazilian Senator Flavio Bolsonaro will face leftist President Luiz Inacio Lula da Silva in a runoff of the presidential election later this month, after he exceeded expectations in Sunday's first-round vote with a slight lead over the incumbent.
Russia says no plague cases have been detected among contacts of a laboratory worker who died in Siberia, with most tests negative for infectious diseases and many quarantined people already released.
Iran's Oil Minister Mohsen Paknejad has resigned, with Hamid Bovard, chief executive of the state-owned National Iranian Oil Company (NIOC), appointed as acting oil minister, according to Iranian state media.
Candidates elected to Bosnia and Herzegovina's three-member presidency declared victory after preliminary unofficial results showed Denis Becirovic leading the Bosniak seat, Darijana Filipovic ahead in the Croat seat and Zeljka Cvijanovic likely retaining the Serb seat.
Space-agency chiefs and industry leaders met to discuss lunar exploration, satellite networks and orbital security on Tuesday as a major global space congress entered its second day.
Police fired tear gas at protesters blockading French high schools on Tuesday as students, teachers and parents took to the streets on the biggest day of action in a wave of demonstrations against understaffed and dilapidated classrooms.
A large Ukrainian drone attack on Moscow and the surrounding region has killed two people, damaged homes and sparked a major fire at a key fuel facility, according to Russian officials and military bloggers.
Kenya has confirmed its first case of Ebola after a Kenyan citizen who had travelled from the Democratic Republic of Congo (DRC) died in Nairobi, prompting health authorities to launch an urgent contact-tracing operation.
A regional conference on Afghanistan in Moscow ended on Monday without a joint statement after Pakistan and the Afghan Taliban delegation failed to agree on wording about terrorism. It was the first time since the inaugural meeting that participants failed to issue a joint statement.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment